$Cassava Sciences Warrants (SAVAW.US)$ New Recent January MD...
$Cassava Sciences Warrants(SAVAW.US$ New Recent January MDPI Scientific Article with Bullish statement about Simufilam. ’Another important aspect of dementia research is the development of new therapeutic approaches aimed at curing the disease or alleviating its symptoms. Hoau-Yan Wang and colleagues [10] investigated the molecular mechanisms of simufilam, a novel oral drug candidate in phase 3 clinical trials for Alzheimer’s dementia. The authors showed that simufilam reduces Aβ42 binding to α7nAChR. They also showed that FLNA binds to several inflammatory receptors in addition to Toll-like receptor 4 (TLR4) in postmortem human AD brains and in AD transgenic mice. These aberrant FLNA connections were disrupted by simufilam. Simufilam also reduced inflammatory cytokine release from Aβ42-stimulated human astrocytes. Taken together, these data suggest that simufilam may promote brain health by disrupting abnormal FLNA receptor interactions that are critical for AD pathogenic pathways.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
